Targeting erbB receptors [PDF]
Seminars in Cell & Developmental Biology, 2010 Our work is concerned with the origins and therapy of human cancers. Members of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, also known as erbB or HER receptors, are over expressed and/or activated in many types of human tumors and represent important therapeutic targets in cancer therapy.
Zheng, Cai +6 more
openaire +2 more sources
PLoS ONE, 2011 BackgroundBetacellulin (BTC), a member of the epidermal growth factor family, is known to play an important role in regulating growth and differentiation of pancreatic beta cells.
Yoon Sin Oh +4 more
doaj +1 more source
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. [PDF]
, 2016 Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR).
Adams, Stephen R +10 more
core +1 more source
The ErbB2 receptor in gastric cancer. the quick-change artist [PDF]
, 2015 The ErbB family of receptors is providing the oncogenic signals necessary to cells to become transformed. In gastric cancer (GC) the ErbB2 (HER2) expression is associated with a poor prognosis, but addition of ErbB-targeted therapeutics to chemotherapy ...
Alimandi, Maurizio +2 more
core +1 more source
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Breast Cancer: Targets and Therapy, 2021 Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University ...
Salkeni MA, Rizvi W, Hein K, Higa GM
doaj
C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy
The International Journal of Biological Markers, 1999 Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj +1 more source
ErbB polymorphisms: Insights and implications for response to targeted cancer therapeutics
Frontiers in Genetics, 2015 Advances in high-throughput genomic-scanning have expanded the repertory of genetic variations in DNA sequences encoding ErbB tyrosine kinase receptors in humans, including single nucleotide polymorphisms (SNPs), polymorphic repetitive elements ...
Moulay A Alaoui-Jamali +2 more
doaj +1 more source
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]
, 2014 Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J. +6 more
core +1 more source
Identification of the zinc finger 216 (ZNF216) in human carcinoma cells. A potential regulator of EGFR activity [PDF]
, 2016 Epidermal Growth Factor Receptor (EGFR), a member of the ErbB family of receptor tyrosine kinase (RTK) proteins, is aberrantly expressed or deregulated in tumors and plays pivotal roles in cancer onset and metastatic progression.
Calogero, Antonella +10 more
core +8 more sources
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]
, 2014 The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L. +8 more
core +6 more sources